Alliance for Clinical Trials in Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).
Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.
Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.
Top-decile sponsor footprint
Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
446 total, page 8 of 9
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
NCT00003611
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005820
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00005964
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00005646
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005810
Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite
NCT00031707
Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels
NCT00031746
Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer
NCT00005059
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
NCT00004235
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
NCT00004857
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
NCT00004933
Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT00004893
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
NCT00004239
Positron Emission Tomography in Determining Stage of Esophageal Cancer
NCT00004867
Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
NCT00004055
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
NCT00004190
Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
NCT00003900
High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer
NCT00003623
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
NCT00004138
Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00004139
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT00003829
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849
Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer
NCT00003831
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
NCT00003901
Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia
NCT00031759
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
NCT00003863
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00003996
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
NCT00003855
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
NCT00003704
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00003612
Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer
NCT00003854
Topotecan in Treating Patients With Myelodysplastic Syndrome
NCT00003675
Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00003812
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00003834
Genetic Study in Patients With Stage II or Stage III Colon Cancer
NCT00003833
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
NCT00003621
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003762
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
NCT00003931
Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases
NCT00003724
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00003700
Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer
NCT00003692
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
NCT00003600
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
NCT00003674
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
NCT00003666
Capsaicin Lozenges in Treating Patients With Mucositis Caused by Radiation Therapy
NCT00003610
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NCT00003594
Docetaxel in Treating Patients With Solid Tumors
NCT00003565
Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer
NCT00003566
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00003546
Gene Testing in Patients With Colon Cancer
NCT00003571
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 209 |
| Phase 3 | 142 |
What is open in the Alliance for Clinical Trials in Oncology pipeline
29 recruiting of 446 indexed (7% open); 346 completed (78%).
Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide
Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 446 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- University of Virginia · 449 trials · 22% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 7% open enrollment (± trial volume)
- National Institutes of Health Clinical Center (CC) · 7% recruiting · 338 trials
- Insmed Incorporated · 6% recruiting · 31 trials
- NICHD Neonatal Research Network · 7% recruiting · 61 trials
- Hennepin Healthcare Research Institute · 6% recruiting · 63 trials
Related
What to do with this Alliance for Clinical Trials in Oncology page
446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.
- 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.